Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2002, Pages 45-48

  Kokkas, B ^a   Kotridis, P ^a   Karamouzis, M ^a   Kanonidis, I ^a   Sakadamis, G ^a   Dadous, G ^a   Haritos, S ^a   Kyriakou, P ^a   Theodossiadis, I ^a   Papadopoulos, P C ^a   Mirtsou Fidani, V ^a   Papadopoulos, Constantine L ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Atrial natriuretic peptide; Ca2+ blockers; Hypertension; Verapamil

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; VERAPAMIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HEART LEFT ATRIUM PRESSURE; HEART VENTRICLE; HUMAN; LONG TERM CARE; MALE; PROTEIN DETERMINATION;

ADMINISTRATION, ORAL; AGED; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; VERAPAMIL;

EID: 0036212212     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190404     Document Type: Article

References (20)

1. Plasma atrial natriuretic peptide in essential hypertension after angiotensin converting enzyme inhibition
2. 1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients
3. 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients
4. Beta blockers and atrial natriuretic peptide (ANP) in hypertension
5. Verapamil. An update review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension
6. Atriopeptides
7. 2+entry blockers
8. Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension
9. Differential effects of nifedipine on plasma atrial natriuretic peptide in normal subjects and hypertensive patients
10. Increase of plasma atrial peptide levels after sublingual administration of nifedipine in essentially hypertensive patients
11. Short term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension
12. Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aidosterone system, and blood pressure in essential hypertension
13. Effects of nitrendipine on blood pressure, renin-angiotensin system and atrial natriuretic peptide in hypertensive type I diabetic patients
14. Role of cAMP and calcium influx in endothelin-1 induced ANP release in rat cardiomyocytes
15. Dinstinct roles for L- and T-type Ca (2+) channels in regulation of atrial ANP release
16. Regulation of atrial natriuretic factor secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C
17. Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by ATI receptor antagonism and ACE inhibition in normotensive and hypertensive rats
18. Angiotensin II-depended down regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats
19. Beta-adrenergic antagonist propranolol potentiates hypertensive action of natriuretic peptides
20. Potentiation of natriuretic peptide action by beta-adrenergic blocker carvedilol in hypertensive rats: A new antihypertensive mechanism